QIAGEN entered its Q1 2026 earnings week already nursing a 17% one-month decline. The report did nothing to arrest the slide — and the Street's response was swift and unanimous.
Q1 sales came in at $492m, missing the $498m consensus estimate. Adjusted EPS of $0.54 matched expectations, but the forward picture was the real damage. Full-year 2026 EPS guidance was trimmed to at least $2.43, below the $2.51 consensus, while the revenue outlook was held at $2.11bn–$2.13bn against a street estimate of $2.18bn. The culprit was QuantiFERON, QIAGEN's immigration-linked tuberculosis testing franchise, where volumes slumped as US immigration enforcement activity dampened demand — a macro headwind that is hard to diversify away quickly.
The analyst reaction sharpened a narrative that had already been turning. The most notable move came from JP Morgan's Casey Woodring, who cut the price target from $60 to $45 last week while keeping an Overweight rating — a meaningful trim that signals reduced conviction even from the bulls. Citigroup and Barclays both lowered their targets (to $38 each) while holding their ratings flat, and Baird used the dip to upgrade to Outperform with a $43 target. The net picture: the Street is not abandoning QIAGEN, but targets have compressed hard. The mean sits at $47.67, implying roughly 40% upside from the current $34 — a gap that reflects either genuine value or the lag of targets catching down to reality. One notable data-consistency caveat: the analyst consensus mean will likely shift further once the post-earnings round of cuts is fully priced in.
QIAGEN's factor scores paint a complicated picture. The analyst recommendation differential ranks in the 97th percentile and the dividend score sits at the 95th — both reflecting relatively favourable positioning relative to peers. But EPS momentum over both 30-day and 90-day windows is well below average (30th and 36th percentiles respectively), and the forward EPS growth indicator ranks in the bottom quintile of the universe. That combination — healthy dividends and positive analyst sentiment held against weakening earnings momentum — describes a stock that the Street still believes in structurally but where near-term earnings dynamics are deteriorating. Valuation offers some support: the trailing P/E has compressed to around 13.5x and the EV/EBITDA is running near 9.2x, reflecting the de-rating that has accompanied the share-price slide.
Short positioning tells the less dramatic part of this story. Short interest is around 2.8% of the free float — noticeable but far from extreme. It edged up roughly 4% over the past week to approximately 6 million shares, though it has been drifting in a tight range through most of April. More telling is the lending market: availability is exceptionally loose at over 1,165% of short interest, meaning there are more than eleven times as many shares available to borrow as there are currently shorted. Cost to borrow is just 0.56% — and has actually eased 24% over the past week from a mid-April peak near 0.74%. The borrow market is not signalling a crowded short. Options positioning is similarly relaxed: the put/call ratio at 0.12 is only marginally above its 20-day average of 0.10. There is no options-market panic here.
Peer performance over the past week puts the QIAGEN move in context. While RVTY climbed 8.4% and ILMN rebounded 9.6%, QIAGEN finished the week down 0.06%. BRKR and RGEN gained 4.8% and 7.0% respectively. The sector saw a broad bounce — QIAGEN didn't participate, weighed down by an earnings print that reminded investors the QuantiFERON headwind is real and not easily offset elsewhere in the portfolio.
Wellington Management added 741,000 shares through Q1, T. Rowe Price added 861,000, and Boston Partners built a position of nearly 1.83 million shares — among the largest institutional moves in recent filings. BlackRock remains the largest holder at 9.2% and trimmed only marginally. These institutional flows show active managers still building exposure, though the filing dates mostly predate the post-earnings gap.
The next thing to watch is whether analyst targets begin to cluster closer to the current price — or whether the QuantiFERON volume trajectory in Q2 provides evidence that the immigration-testing headwind is stabilising rather than deepening.
See the live data behind this article on ORTEX.
Open QGEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
